GE HealthCare Wins CE Mark for MINItrace Magni Cyclotron

GE HealthCare announced on October 15, 2026, that its MINItrace Magni cyclotron has achieved CE Mark and that its PETtrace Solid Target Platform is expanding beyond Gallium-68 with support for Copper-64 production, according to a company news release. The company said the two developments reflect its focus on helping institutions build the production capabilities behind their molecular imaging programs, from establishing local PET radioisotope production to supporting research into emerging radiopharmaceuticals.

For healthcare providers building or expanding a positron emission tomography program, access to tracers is an important consideration, the release states. Many PET radioisotopes have short half-lives, making proximity between production and use a factor in supply planning. Cyclotrons produce these radioisotopes, which can then be incorporated into radiotracers used in PET imaging. Local production can give providers greater control over supply and scheduling while reducing reliance on external production and transportation, according to the company.

“The molecular imaging landscape is being reshaped by the expansion of theranostics, the introduction of new PET tracers, and demand across oncology, neurology and cardiology,” said Erez Levy, Vice President of Molecular Imaging at GE HealthCare. He said that as tracer portfolios broaden, providers need reliable access to radioisotopes and the flexibility to respond to changing clinical needs, calling for a longer-term view of radiopharmaceutical production that supports established services while allowing institutions to prepare for new clinical and research applications.

Compact Design and Automated Operation

For institutions seeking to establish or expand in-house production, MINItrace Magni combines a compact, self-shielded design with simplified operation, according to GE HealthCare. The cyclotron is designed to produce Fluorine-18, Carbon-11, Oxygen-15 and Nitrogen-13 for PET tracers.

The system features an intuitive user interface and a three-click workflow designed to streamline routine production steps, the company said. Its automated features include auto-tuning, which prepares the cyclotron and targets, tunes the beam and manages target irradiation.

GE HealthCare said producing the radioisotope is only one part of preparing a PET tracer. Used with the company’s TRACERcenter Solutions, MINItrace Magni is designed to support a broader PET radiopharmacy workflow based on an institution’s clinical, operational and tracer-production needs. The company said this approach is intended to help providers develop tailored local radiopharmaceutical capabilities aligned with the requirements of their molecular imaging programs, while accounting for both current and future departmental needs. GE HealthCare’s cyclotron product documentation describes TRACERcenter Solutions as bringing the technology, service and equipment that make up a tracer production facility together in one comprehensive solution.

Copper-64 and the Solid Target Platform

The addition of Copper-64 extends the PETtrace Solid Target Platform beyond Gallium-68, for which it was introduced in 2022, and Zirconium-89, which was made available in early 2026, the company said. According to the release, the capability broadens the range of isotopes that may be produced using PETtrace cyclotron infrastructure, allowing customers to build on the platform as their isotope needs evolve.

Copper-64 enables PET imaging and is also being studied with investigational Copper-67 agents as a potential diagnostic and therapeutic pair, the release states. That research sits within the broader field of theranostics, which connects molecular imaging with targeted radionuclide therapy. Clinical research is evaluating Copper-64-labeled compounds in areas including prostate cancer and HER2-positive breast cancer, according to the company.

GE HealthCare said its capabilities in cyclotrons, targetry, radiochemistry synthesis, molecular imaging and services are intended to help institutions establish solid-target production as part of a broader radiopharmacy workflow. The company’s product documentation states that the Solid Target Platform integrates each component of the production chain, with purification and labeling handled on the FASTlab synthesizer, cassette-based plug-and-play operation by a single operator, and multi-Curie production.

Nicolas Durand-Schaefer, General Manager, Molecular Imaging, International, at GE HealthCare, called the CE Mark “an important milestone for a compact, versatile cyclotron designed to support local radioisotope production” that enables healthcare providers to build radiopharmacy capabilities without the need for large-scale production infrastructure. He said adding Copper-64 to PETtrace broadens the platform’s capabilities to support copper-based imaging and theranostics research, and that the company’s focus is on helping institutions connect the practical demands of running a radiopharmacy with their longer-term clinical and research ambitions.

GE HealthCare said both developments build on more than 40 years of company experience in cyclotron and PET radiopharmacy technologies. The company said representatives will be at its booth during the European Association of Nuclear Medicine’s 2026 Annual Meeting, scheduled for October 17 to 21 in Vienna, Austria.